

Special Issue

New Challenges for Gastric Cancer—Gut Microbiota, Post-eradication and Chemotherapy

Message from the Guest Editors

Although gastric cancer is declining due to the establishment of *Helicobacter pylori* (*H. pylori*) eradication therapy, there are still many gastric cancer deaths worldwide. New findings are still being found to overcome the disadvantages of gastric cancer in patients. Recently, it has been reported that *H. pylori*-infected patients and patients with intestinal metaplasia have a high diversity of intestinal microbiota, and there is an association with gastric cancer in the stomach microbiota. In addition, gastric cancer after *H. pylori* eradication has different characteristics from conventional *H. pylori*-associated gastric cancer, so we must continue to acquire new knowledge about this cancer type. In terms of treatment, minimally invasive therapy for early-stage gastric cancer has become widespread, and recently, chemotherapy, including immune checkpoint inhibitors, has been advancing at a rapid rate. In this Special Issue, we will collect the latest findings in this new phase of gastric cancer.

Guest Editors

Dr. Kazunari Murakami

Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu 879-5593, Japan

Dr. Kazuhiro Mizukami

Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu 879-5593, Japan

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/182980

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)